Publication

• [2014]
• - Hong CY, Kim SY, Lee HJ, Lee SE, Lim SC, Rhee JH, Lee JJ. A bacterial flagellin in combination with proinflammatory cytokines activates human monocyte-derived dendritic cells to generate cytotoxic T lymphocytes having increased homing signals to cancer. J Immunother. 2014 Jan;37(1):16-25
• - Hong CY, Lee HJ, Kim HJ, Lee JJ. The lymphoid chemokine CCL21 enhances the cytotoxic T lymphocyte-inducing functions of dendritic cells. Scand J Immunol.2014 Mar;79(3):173-80
• - Jung SH, Lee YK, Lee HJ, Choi NR, Vo MC, Hoang MD, Lim MS, Nguyen-Pham TN, Kim HJ, Lee JJ. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. Exp Hematol. 2014 Jan 6. pii: S0301-472X(14)00004-6. doi: 10.1016/j.exphem.2013.12.008.
• - Jung SH, Yang DH, Ahn JS, Lee SS, Ahn SY, Kim YK, Kim HJ, Lee JJ. Decreased body mass index is associated with poor prognosis in patients with multiple myeloma. Ann Hematol. 2013 Dec 6.
• [2013]
• - Ahn JS, Yang DH, Jung SH, Chae YS, Sohn SK, Yhim HY, Kwak JY, Lee SR, Kim YK, Kim HJ, LeeJJ. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol. 2013;92(6):789-97.
• - Hwang EC, Lim MS, Im CM, Kwon DD, Lee HJ, Nguyen-Pham TN, Lee YK, LeeJJ. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells. Scand J Immunol. 2013;77(2):117-24.
• - Jung SH, Bae SY, Ahn JS, Kang SJ, Yang DH, Kim YK, Kim HJ, LeeJJ. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. Int J Hematol. 2013;97(3):382-7.
• - Jung SH, Park H, Ahn JS, Yang DH, Kim MY, Kim YK, Kim HJ, LeeJJ. Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. Int J Hematol. 2013;97(1):92-7.
• - Ahn JS, Rew SY, Yang DH, Jung SH, Kang SJ, Kim MY, Lee SS, Kim YK, Kim HJ, LeeJJ. Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. Blood Res. 2013;48(1):35-9.
• - Yang DH, Ahn JS, Byun BH, Min JJ, Kweon SS, Chae YS, Sohn SK, Lee SW, Kim HW, Jung SH, Kim YK, Kim HJ, Bom HS, LeeJJ. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92(4):471-9.
• - Ahn JS, Yang DH, Duk Choi Y, Jung SH, Yhim HY, Kwak JY, Sung Park H, Shin MG, Kim YK, Kim HJ, LeeJJ. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Am J Hematol. 2013 Sep;88(9):774-9
• [2012]
• - Nguyen-Pham TN, Yang DH, Nguyen TA, Lim MS, Hong CY, Kim MH, Lee HJ, Lee YK, Cho D, Bae SY, Ahn JS, Kim YK, Chung IJ, Kim HJ, Lee JJ. Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy. Cell Mol Immunol. 2012 Jan;9(1):45-53. doi: 10.1038/cmi.2011.23. -
• - Lee HJ, Hong CY, Jin CJ, Kim MH, Lee YK, Nguyen-Pham TN, Lee H, Park BC, Chung IJ, Kim HJ, Lee JJ. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer. Cell Mol Immunol. 2012 Mar;9(2):175-83.
• - Lee HJ, Hong CY, Kim MH, Lee YK, Nguyen-Pham TN, Park BC, Yang DH, Chung IJ, Kim HJ, Lee JJ. In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential target for colorectal cancer. Exp Mol Med. 2012 Jan 31;44(1):60-7.
• - Yang DH, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh CW, Lee JJ. Pilot trial of yttrium-90 ((90)Y)-ibritumomab tiuxetan consolidation following R-CHOP chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(5):807-11.
• - Ahn JS, Yang DH, Jung SH, Park HC, Moon JH, Sohn SK, Bae SY, Kim YK, Kim HJ, Lee JJ. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma. Ann Hematol. 2012;91:1023-30.
• - Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ. Immunotherapy using Dendritic Cells against Multiple Myeloma: How to improve? Clin Dev Immunol. 2012;2012:397648.